Señales en vivo de INVA | Maximiza tus Ganancias con Getagraph.com

VENDER 119700 min ago

@ $15.84

Emitido: 14 feb 2024 @ 15:17

Retorno: -1.96%

Señal anterior: feb 14 - 13:26

Señal anterior: Comprar

Retorno: 0.54 %

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 16:00):

Stats
Volumen de hoy	385 342
Volumen promedio	713 250
Capitalización de mercado	970.91M
EPS	$0 ( 2024-02-27 )
Próxima fecha de ganancias	( $0.170 ) 2024-05-14
Last Dividend	$0.250 ( 2015-09-08 )
Next Dividend	$0 ( N/A )
P/E	7.06
ATR14	$0.00600 (0.04%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	Small Derek A	Sell	1 206	Restricted Stock Units
2024-04-29	Small Derek A	Sell	833	Stock Options
2024-03-05	Basso Stephen	Buy	25 899	Non-statutory Stock Option
2024-03-05	Basso Stephen	Buy	12 096	Common Stock
2024-03-05	Ronsheim Matthew	Buy	27 338	Non-statutory Stock Option

INSIDER POWER
89.35
Last 96 transactions
Buy: 2 118 652 \| Sell: 32 095 513

Volumen Correlación

Largo: -0.26 (neutral)

Corto: -0.41 (neutral)

Signal:(24.483) Neutral

Innoviva Inc Correlación

10 Correlaciones Más Positivas
ONEM	0.92
ESSA	0.92
NAKD	0.911
AADI	0.909
AROW	0.908
DSWL	0.906
AZTA	0.905
BSRR	0.904
UK	0.902
SRDX	0.897

10 Correlaciones Más Negativas
NEO	-0.927
TMDX	-0.919
MORF	-0.916
ACVA	-0.913
SGTX	-0.911
SJ	-0.909
MHUA	-0.909
MYNA	-0.907
RMRM	-0.907
MLTX	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Innoviva Inc Correlación - Moneda/Commodity

0.65
( moderate )

0.25
( neutral )

0.00
( neutral )

0.70
( moderate )

0.00
( neutral )

0.27
( neutral )

Innoviva Inc Finanzas

Annual	2023
Ingresos:	$324.26M
Beneficio Bruto:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2023
Ingresos:	$324.26M
Beneficio Bruto:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2022
Ingresos:	$331.34M
Beneficio Bruto:	$317.55M (95.84 %)
EPS:	$-1.080

FY	2021
Ingresos:	$391.87M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$2.62

Financial Reports:

No articles found.

Innoviva Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Innoviva Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.68 - No dividend growth expected in the near future

Information

First Dividend	$0.250	2014-08-26
Last Dividend	$0.250	2015-09-08
Next Dividend	$0	N/A
Payout Date	2015-09-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	3.77	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.68
Div. Directional Score	7.39	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

3.77

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2014	$0.500	1.84%
2015	$0.750	5.65%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.573	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.145	1.200	5.18	6.22	[0 - 0.3]
returnOnEquityTTM	0.297	1.500	7.81	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.03	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	5.07	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.360	-1.500	4.00	-6.00	[0 - 0.6]
interestCoverageTTM	9.70	1.000	7.52	7.52	[3 - 30]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.21	2.00	8.90	10.00	[0 - 20]
debtEquityRatioTTM	0.663	-1.500	7.35	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.832	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.592	1.000	0.162	0.162	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.315	1.000	9.36	9.36	[0.2 - 2]
assetTurnoverTTM	0.252	0.800	-1.650	-1.320	[0.5 - 2]
Total Score				11.10

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.48	1.000	9.55	0	[1 - 100]
returnOnEquityTTM	0.297	2.50	8.59	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.103	1.500	-2.64	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.449	1.000	1.265	0	[0.1 - 0.5]
Total Score				3.68

Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Actualizaciones en tiempo real para Innoviva Inc [INVA]

Upcoming Earnings Alert

Innoviva Inc Dividend Information - Ex Dividend Knight

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)